Washington, DC — The Food and Drug Administration (FDA) has approved a drug that contains an active ingredient derived from the cannabis plant. The drug, Epidiolex, an oral solution containing cannabidiol (CBD), will be the first and only FDA-approved CBD drug on the market. The FDA has approved Epidiolex for use only in the treatment of two rare seizure disorders (Dravet Syndrome and Lennox-Gastaut Syndrome), and is the first FDA-approved treatment for patients suffering from Dravet syndrome. While there have been other medications that mimic the natural cannabinoids found in cannabis that have received FDA approval, Epidiolex is the first non-synthetic medication to be derived directly from the cannabis plant. The FDA’s approval of Epidiolex shows that it is possible to make medications from complex plant extracts.